MDxHealth SA
Research MDxHealth SA (MDXH) on Bullrun: market cap USD 40.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMDXH
- ExchangeNASDAQ
- CountryBelgium
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 40.53M
- Financial periodQ1 2026
- RevenueUSD 27.39M
- Net income-USD 8.87M
- Free cash flow-USD 1.85M
- Gross margin60.7%
Valuation Snapshot
latest market cap is USD 40.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 107.88M | -USD 33.52M | -USD 3.35M | 64.5% | -1.28 | USD 29.03M | USD 86.60M | -USD 12.09M |
| FY2024 | USD 90.05M | -USD 38.07M | -USD 20.69M | 61.2% | -2.33 | USD 46.80M | USD 60.06M | USD 14.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 40.53M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 183.37M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 117.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 107.52M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 107.66M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 148.48M | n/a | n/a | n/a |
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MDxHealth SA's market cap?
MDxHealth SA's market capitalization is USD 40.53M.
What does MDxHealth SA do?
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.